Hemispherx Biopharma,HEB - Losing Ground

Hemispherx Biopharma, Inc

Rochester, NY 6/06/2009 01:16 AM GMT (TransWorldNews)

Hemispherx Biopharma,HEB - Losing Ground

Hemispherx Biopharma, Inc,HEB

CEO of Hemispherx Biopharma is proported to regularly use an eight year old government report to assure investors the company's chronic fatigue syndrome drug will be approved soon.

The evidence is mounting that Carter is seeking to divert investors' attention away from the delayed approval of Ampligen as a treatment for chronic fatigue syndrome. The U.S. Food and Drug Administration was supposed to announce its decision May 25, but on May 26, Hemispherx said the FDA asked for a "brief delay" of one to two weeks.


Wed, May 27, 2009

The Sage Group, a privately held international health care consulting group, announced recently that HemispherX Biopharma  has expanded the mandate for The Sage Group to include, in addition to the strategic partnering efforts related to Ampligen (an experimental immunotherapeutic) for Chronic Fatigue Syndrome, additional partnering efforts related to Ampligen's use to increase the effectiveness of preventative pandemic flu vaccines and the additional role of Alferon LDO (an experimental therapeutic) for treating various types of pandemic flu.

In particular, Sage is assisting HemispherX in its work with the Japanese government in the rapid development of a response strategy for pandemic flu. According to Time Magazine, the number of swine flu cases in Japan are escalating with surprising speed, and health officials are not sure why.

Tue, May 26, 2009

Hemispherx Biopharma, Inc. (NYSE Amex:HEB) today announced that the U.S. Food and Drug administration ("FDA") has advised the company that it may require up to 1-2 additional weeks to take action beyond the scheduled Prescription Drug User Fee Act action date of May 25, 2009 on the New Drug Application for Ampligen(r) (Poly I Poly C12U), a selective TLR3 modulator, for the management of Chronic Fatigue Syndrome. Reason for the possible delay was attributed by the Agency to certain staff scheduling changes which might (or might not) delay the report. Accordingly the Company's development plan for Ampligen(r) continues as described in the recently filed 10Q and 10K, as the FDA did not request additional information from the Company at this time.


Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of new drug therapies for the treatment of viral and immune based chronic disorders. The company's products include Alferon N Injection for the treatment of genital warts; and Ampligen, an experimental drug that is in human clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, HIV, renal cell carcinoma, and malignant melanoma. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of viral diseases and disorders of the immune system. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

Last Trade:      3.02
Day's Range:    2.12 - 4.54
52wk Range:    0.25 - 3.98
Volume:           53,231,174
Avg Vol (3m):    4,834,680
Market Cap:    254.71M


If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.

Investors sign up for our FREE alerts at


Disclaimer: Full disclaimer at

WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.

This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

CONTACT: WhisperFromWallStreet.com



News Alerts

Receive alerts for HEB to your inbox. Sign up for News Alerts

Empty Image

TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.

Empty Image